‘Molecular glues’ are sticking it to cancer
By 
Phillip Broadwith2026-09-15T14:56:00
Compounds that enhance selected protein–protein interactions to interfere with signalling or send proteins to be destroyed are making it possible to influence processes that were previously considered ‘undruggable’
‘Molecular glues’ that work by modulating protein–protein interactions are one of several emerging new types of drugs that are now beginning to see decades of work translate into success in clinical trials and drug approvals. US approval of Revolution Medicines’ Rasonque (daraxonrasib) to treat pancreatic cancer follows closely on the heels of accelerated approval for Bristol Myers Squibb’s Zenbexus (iberdromide) to treat multiple myeloma.